August 28, 2020
A case-by-case approach must be taken when considering the use of Novartis Pharma’s heart failure treatment Entresto (sacubitril valsartan sodium hydrate) in patients with preserved ejection fraction, a Japanese cardiologist said on August 27 at a company-sponsored seminar. An angiotensin...read more